Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06855095
PHASE2/PHASE3
Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial
Sponsor: The Netherlands Cancer Institute
View on ClinicalTrials.gov
Summary
According to current guidelines, patients have to withhalt long-acting somatostatin analogues (LA-SSA) for 4-6 weeks prior to every 177Lutetium-DOTATATE administration. The primary objective of the study is to investigate the effect of LA-SSA on the absorbed dose in tumor lesions during PRRT.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
39
Start Date
2024-06-25
Completion Date
2027-03-01
Last Updated
2025-03-03
Healthy Volunteers
No
Conditions
Interventions
DRUG
Somatostatin analog
Timing of LA-SSA injection prior to PRRT (either 4-6 weeks or 1-7 days).
Locations (1)
Antoni van Leeuwenhoek
Amsterdam, Netherlands